Stock 4746 FORMOSA LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Formosa Laboratories, Inc.

Equities

4746

TW0004746003

End-of-day quote Taiwan S.E.
Other stock markets
 23:00:00 14/05/2024 BST 		5-day change 1st Jan Change
93.1 TWD -0.11% Intraday chart for Formosa Laboratories, Inc. -4.22% -8.73%
03-12 Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-12 Formosa Laboratories, Inc. Approves Dividend Distribution for Full Year Ended December 31, 2023 CI

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FORMOSA LABORATORIES, INC. Stock Formosa Laboratories, Inc.
-8.73% 346M -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.37% 588B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.69% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.66% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.73% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.83% 239B
B+
NOVARTIS AG Stock Novartis AG
+9.93% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.95% 200B
A+
AMGEN INC. Stock Amgen Inc.
+11.13% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
0.00% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4746 Stock
  4. Ratings Formosa Laboratories, Inc.